

Spark Therapeutics, Inc.  
Form 8-K  
November 25, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 25, 2015**

**Spark Therapeutics, Inc.**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**3737 Market Street**

**001-36819**  
**(Commission**

**File Number)**

**46-2654405**  
**(IRS Employer**

**Identification No.)**

**19104**

Edgar Filing: Spark Therapeutics, Inc. - Form 8-K

**Suite 1300**

**Philadelphia, PA**

**(Address of Principal Executive Offices)**

**(Zip Code)**

**Registrant's telephone number, including area code: (855) 772-7589**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

Spark Therapeutics, Inc. (the Company) is filing the risk factors attached to this Current Report on Form 8-K to update and supersede the risk factors contained in its periodic reports filed with the U.S. Securities and Exchange Commission (the SEC) pursuant to the Securities Exchange Act of 1934, as amended, including those under the heading Item 1A. Risk Factors in its Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 25, 2015 and its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015, filed with the SEC on November 6, 2015.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

**Exhibit**

<b>No.</b>	<b>Exhibit Description</b>
99.1	Risk Factors

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SPARK THERAPEUTICS, INC.

Date: November 25, 2015

By: /s/ Joseph W. La Barge  
Joseph W. La Barge

General Counsel

**Exhibit Index**

Exhibit 99.1 Risk Factors